2023-04-18 08:59:59 ET
- Medicare has agreed to cover for Guardant Health's ( NASDAQ: GH ) Guardant360 Response test, which is used to assess a cancer patient's response to immune checkpoint inhibitor therapy.
- The blood test monitors molecular response through changes in circulating tumor DNA (ctDNA) levels.
- The test is covered for fee-for-service Medicare patients with metastatic or inoperable solid tumors who are receiving immune checkpoint inhibitor therapy.
- Examples of immune checkpoint inhibitors include Merck's ( MRK ) Keytruda (pembrolizumab), Bristol-Myers Squibb's ( BMY ) Yervoy (ipilimumab) and Opdivo (nivolumab), and Roche ( OTCQX:RHHBY ) Genentech unit's Tecentriq (atezolizumab).
- Read why Seeking Alpha contributor Ryan Licwinko has a hold rating on Guardant Health ( GH ).
For further details see:
Guardant Health cancer immunotherapy response test covered by Medicare